Torna ai risultati
Scheda bibliografica · Consultazione e accesso
Artículo

Formulation, development and optimization of ofloxacin FDDS sustained release for UTI and H. pylori

Muhammad Afnan et al · AMMANIF · 2024

Materiale supplementare disponibile
Lettura rapida. Controlla i dati essenziali della risorsa e accedi al contenuto con il pulsante principale. La scheda mostra solo le informazioni necessarie per identificare, citare e aprire l’opera.

Accesso alla risorsa

Elegí el proveedor desde el que querés acceder.

DOAJ DOAJ Articles
Entrar por DOAJ
NODOVOX DOAJ - Open Access Journals
Entrar por NODOVOX
Accesso principale

Materiale supplementare disponibile

El enlace apunta a material asociado, anexos, tablas, datos o página complementaria. No se marca como libro/texto completo.
Apri materiale
Otras opciones de acceso Elegí el proveedor disponible para esta ficha.
Importación CSV DOAJ - Open Access Journals
Acceder por Importación CSV
DOAJ OAI-PMH DOAJ Articles
Acceder por DOAJ OAI-PMH

Altre opzioni disponibili

Se la risorsa è presente su più piattaforme, puoi scegliere dove aprirla.

Importación CSV DOAJ - Open Access Journals Accesso disponibile
Apri
DOAJ OAI-PMH DOAJ Articles Accesso disponibile
Apri

Riepilogo

Descripción general del contenido del recurso.

Objective: Development & Optimization of Ofloxacin Floating tablets to enhance gastric retention time. Sustained release effect of formulation will reduce the dosing frequency for UTIs and prolonged local effect will benefit against H-pylori infection. Materials: Pre formulation tests were performed which include bulk characteristics and flow properties. Post formulation studies include weight variation, thickness, content uniformity, hardness, friability, dissolution studies, release kinetics and compatibility & stability analysis. Kinetic studies were done and models were applied to understand the drug release mechanism. Accelerated stability analysis was also done for time period of 6 months. Results: All pre formulation tests were within range of USP standards, all the formulations showed good buoyancy. The in-vitro dissolution testing showed that F2 released drug at much slower rate, 64.97% within 24 hrs. F3 & F4 released ofloxacin at faster rate, 98.6% & 99.90% respectively, however, F1 released 91.66% drug within 24 hrs. F1 followed Higuchi model, F2 & F3 followed 1st order kinetics and F4 followed 1st order & Higuchi model. For F1, FTIR & DSC analysis curves showed no interaction or change of state of ofloxacin. Conclusion: Formulation F1 was proved to be the optimized formulation and followed non-Fickian release independent of concentration of drug also confirmed from Korsmeyer-Peppas equation. The Stability analysis also proved that F1 is the best fit formulation to be used as Floating Drug Delivery System of Ofloxacin. Stability analysis proved that polymers used in F1 formulation were effective effervescent agents and made the formulation optimized and efficacious.

Come citare

Elegí el formato que necesitás y copiá la referencia al portapapeles.

APA 7

al, M. A. E. (2024). Formulation, development and optimization of ofloxacin FDDS sustained release for UTI and H. pylori. https://www.ammanif.com/journal/jcp/index.php/home/article/view/72

MLA

al, Muhammad Afnan et. "Formulation, development and optimization of ofloxacin FDDS sustained release for UTI and H. pylori." 2024. https://www.ammanif.com/journal/jcp/index.php/home/article/view/72.

Chicago

al, Muhammad Afnan et. 2024. "Formulation, development and optimization of ofloxacin FDDS sustained release for UTI and H. pylori.". https://www.ammanif.com/journal/jcp/index.php/home/article/view/72.

Harvard

al, M. A. E. 2024, Formulation, development and optimization of ofloxacin FDDS sustained release for UTI and H. pylori, AMMANIF, available at: https://www.ammanif.com/journal/jcp/index.php/home/article/view/72 [Accessed 8 Aug. 2026].

Condividi e stampa

Salva la scheda, copia il link permanente o stampala in PDF.

Esporta riferimento

Esporta il record nei formati più comuni per usarlo con un gestore bibliografico.

Dettagli della risorsa

Informazioni bibliografiche utili per verificare che sia il materiale corretto.

Titolo
Formulation, development and optimization of ofloxacin FDDS sustained release for UTI and H. pylori
Autore / collaboratori
Muhammad Afnan et al
Editore
AMMANIF
Anno di pubblicazione
2024
ISSN
2521-0521
ISSN
2521-0521
Lingua
Inglés

Soggetti

Esplora risorse correlate a partire da questi soggetti.

Copiato